---
run_id: halo-evidence-vs-diagnosis-validation-v9-generic-advice-prompted-04
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: generic_advice_prompted
run_number: 4
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 405
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `generic_advice_prompted`, run 4 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 405, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) are being artificially inflated by financial incentives (bundle pricing) and sales narratives (roadmap promises). Your leading indicators (usage) are misleading because they reflect manager-led enablement exercises rather than organic adjuster workflow.

The core risk is that DraftPath provides **perceived value** to the buyer (the manager/executive) but lacks **functional utility** for the user (the adjuster). In B2B workflow software, this gap is a leading indicator of churn.

The **Usage Quality Sprint** only tells you *that* users are leaving; it doesn't tell you *why*. The **Commercial Cleanroom** is a dangerous gamble that risks revenue and damages sales morale for the sake of data you can get more cheaply elsewhere. **Scaling broadly** based on current data is a recipe for a massive churn event in 12 months. **Narrowing to health-liability** is premature, as you don't yet know if the problem there is a product limitation or a regulatory reporting gap.

The **Claim File Review** is the only option that attacks the "ground truth." By auditing actual claim files, you move past vanity metrics and sentiment. You will discover if the "lack of wrong recommendation tickets" is because the tool is accurate, or because adjusters have simply stopped trusting it and are overriding it silently. This provides the necessary evidence to decide whether next year's budget should go toward *scaling* (if utility is high) or *pivoting* (if the logic is flawed).

### The Tradeoffs
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**.

**What you give up:** You sacrifice real-time, quantitative visibility into the "leaky bucket." You will not have a weekly dashboard showing exactly when adjusters drop off. You are trading *breadth* (knowing how many people quit) for *depth* (knowing exactly why the product failed a specific claim). You are betting that a qualitative understanding of "impossible to explain" actions is more valuable than a quantitative chart of declining return rates.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manually intensive. While you are spending weeks auditing files, the "silent churn" happening in your regional carrier accounts will continue. Because this method doesn't provide a "hard number" as quickly as the Usage Quality Sprint, you may struggle to convince a commercially-driven executive team that the product is failing if the bookings numbers continue to look strong in the short term.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discover that your "bundle pricing" represents more than 50% of your expansion revenue. If the financial distortion is that severe, you no longer have a product problem—you have a pricing and sales integrity problem. In that case, the only way to save the company's valuation is to immediately stress-test whether anyone will pay a fair market price for DraftPath without the bundle.
